Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citchem X is an oral combination syrup developed by Ultrachem Pharmaceuticals for the management of productive coughs and symptoms associated with various broncho-pulmonary disorders, including acute and chronic bronchitis, bronchial asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. The formulation contains four active ingredients: ambroxol (a mucolytic agent that thins and breaks down mucus), guaifenesin (an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions), terbutaline (a selective beta-2 adrenergic receptor agonist that acts as a bronchodilator to relax airway smooth muscle), and menthol (which provides a cooling sensation and relieves throat irritation). Together, these components work synergistically to facilitate mucus clearance, ease breathing, and soothe throat discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol + guaifenesin + menthol + terbutaline.